Here are relevant reports on : diabetes-devices-market
-
Asia Pacific Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors (Auto Injectors), Implantable, Transmucosal, Nasal, Syringes), Application (Cancer, Diabetes), Care Setting (Hospital, Home Care) - Forecast to 2031
The Asia Pacific pharmaceutical drug delivery market, valued at US$457.9 million in 2025, stood at US$479.7 million in 2026 and is projected to advance at a resilient CAGR of 7.5% from 2026 to 2031, culminating in a forecasted valuation of US$687.9 million by the end of the period. The market growth for drug delivery in the APAC region is steadily expanding due to an increase in disease prevalence, an increase in the adoption rate of biologics, advancements in technologies, and an increase in regional production.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Wearable Injectors Market by Product (On-body, Off-body), Technology (Spring, Motor Driven, Rotary Pump), Usage (Disposable, Reusable), Delivery Method (Bolus, Programmed Infusion), Therapeutic Application (Diabetes, Oncology), End User - Forecast to 2030
The global wearable injectors market, valued at US$10.2 billion in 2024, stood at US$11.3 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$18.9 billion by the end of the period. Key factors contributing to this growth include the rising incidence of chronic diseases such as diabetes, cancer, cardiovascular disorders, and chronic respiratory illnesses.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Patient Engagement Solutions Market by Therapy (CVD, Diabetes, Obesity, Fitness), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, Payer, Patient), Unmet Need, Investment, Market Share, Trends - Global Forecast to 2030
The global patient engagement solutions market, valued at US$25.79 billion in 2024, stood at US$29.33 billion in 2025 and is projected to advance at a resilient CAGR of 12.0% from 2025 to 2030, culminating in a forecasted valuation of US$51.69 billion by the end of the period. The patient engagement solutions market is driven by the growing shift toward patient-centric care, rising adoption of digital health technologies, increasing prevalence of chronic diseases, and the expanding use of mobile apps, portals, and remote monitoring tools to support continuous patient interaction
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Patient Engagement Solutions Market by Therapy (Chronic [Obesity, Diabetes], Women’s Health), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, ASC, Payer, Patient), Unmet Need, Investment - Forecast to 2030
The Asia Pacific patient engagement solutions market is projected to reach USD 7.48 billion by 2030 from USD 3.97 billion in 2025, at a CAGR of 13.5% during the forecast period. Prominent players in the market include McKesson Corporation (US), Veradigm LLC (US), Oracle (US), athenahealth (US), Health Catalyst (US), Cognizant (US), Oneview Healthcare (Ireland), Epic Systems Corporation (US), Medical Information Technology, Inc. (US), Koninklijke Philips NV (Netherlands), Orion Health (New Zealand), Televox (US), Nuance Communications, Inc. (US) (Microsoft), Experian Information Solutions, Inc. (US), TATA Consultancy Services Limited (India), Optum (US), OPEN Health (UK), DKSH (Switzerland), ZS (US), eClinicalWorks (US), blueBRIX (US), Fortunesoft (India), SONIFI Health Incorporated (US), Genzeon (US), and Advantech Co., Ltd. (Taiwan).
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Prefilled Syringes Market by Type (Conventional, Safety), Material (Glass Prefilled Syringe, Plastic), Design (Single-Chamber Prefilled Syringe, Dual-Chamber), Application (Diabetes, Cancer, and Rheumatoid Arthritis), & Region - Global Forecast to 2030
The global prefilled syringe market, valued at US$6.40 billion in 2023, stood at US$7.10 billion in 2024 and is projected to advance at a resilient CAGR of 10.8% from 2024 to 2030, culminating in a forecasted valuation of US$13.14 billion by the end of the period. The market for prefilled syringes is expanding significantly as a result of rising chronic illness rates that necessitate frequent treatment, and growing demand for effective and practical drug delivery methods.
- Published: March 2025
- Price: $ 4950
- TOC Available:
-
Middle East & Africa Injectable Drug Delivery Market by Product (Device, Needle-free injectors, Formulation, Solutions), Formulation Packaging (Vials, Cartridges), Therapeutic Application (Diabetes, Psoriasis), Site of Administration – Forecast to 2031
The Middle East & Africa injectable drug delivery market, valued at US$15.46 billion in 2025, stood at US$16.46 billion in 2026 and is projected to advance at a resilient CAGR of 6.5% from 2026 to 2031, culminating in a forecasted valuation of US$22.54 billion by the end of the period. The demand for fill-and-finish services is increasing, contributing to the growth of the injectable drug delivery market in the Middle East & Africa.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Home Healthcare Market by Product (Therapeutic, Testing, Screening, Monitoring, Mobility Care), Service (Nursing, Infusion Therapy, Rehabilitation, Palliative Care), Indication (Cancer, Diabetes, CVD, Respiratory, Wound Care) - Global Forecast to 2030
The global home healthcare market, valued at US$285.3 billion in 2024, stood at US$309.9 billion in 2025 and is projected to advance at a resilient CAGR of 8.9% from 2025 to 2030, culminating in a forecasted valuation of US$473.8 billion by the end of the period. This growth is driven by the rising elderly population, which is more prone to chronic conditions such as hypertension, diabetes, and cardiovascular diseases, increasing the need for ongoing care at home.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape - Global forecast to 2030
The global active pharmaceutical ingredient market, valued at US$136.22 billion in 2024, stood at US$144.20 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2024 to 2030, culminating in a forecasted valuation of US$198.39 billion by the end of the period. The growth of the active pharmaceutical ingredients market is driven by the surge in demand for complex APIs, such as high-potency API, peptides, oligonucleotides, and increasing government incentives and supply chain reshoring.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
The global biosimilars market, valued at US$32.75 billion in 2024, stood at US$35.04 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2035, culminating in a forecasted valuation of US$72.29 billion by the end of the period. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implantable, Syrups, Gels, Pulmonary, Tablets, Syringes], Application (Cancer, Diabetes), Facility of Use (Hospital, Home Care) -Global Forecast to 2029
The global pharmaceutical drug delivery market, valued at US$1,831.1 million in 2023, stood at US$1,949.4 million in 2024 and is projected to advance at a resilient CAGR of 5.5% from 2024 to 2029, culminating in a forecasted valuation of US$2,546.0 million by the end of the period. The increasing patient population with chronic diseases, coupled with the growing geriatric population, rising technological advancements in pharmaceutical drug delivery products offering enhanced patient convenience and compliance, the growing adoption of home-based and self-administration, rising government initiatives promoting accessibility to pharmaceutical drug delivery, and the increasing demand for biosimilars and biologics are likely to support market growth.
- Published: September 2024
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
